Tuesday, Gilead Sciences Inc (NASDAQ:GILD) reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70. Sales increased 6% year over year to $7.57 billion, beating the consensus ...
A cheap HIV drug appears to reverse vision loss caused by diabetic macular edema Lamivudine caused a dramatic improvement in vision for people with DME The drug comes in pill form, while current ...
To develop “ultra-long-acting” subcutaneous HIV drugs, GlaxoSmithKline's ViiV Healthcare has licensed Halozyme Therapeutics' drug delivery platform for$40 million upfront. (GlaxoSmithKline) () With ...
While people living with HIV can lead virtually normal lives thanks to antiretroviral therapy (ART), HIV persists in a latent state within cellular reservoirs that scientists do not know how to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results